



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

30th September, 2022

Corporate Relationship Department
M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001.

The Manager - Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/ Madam,

Sub: Proceedings of the 39th Annual General Meeting

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time. Please find enclosed herewith the proceedings of the 39th Annual General Meeting held on today i.e., 30th September, 2022

This is for your information and records.

Thanking you,

Yours Faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: a.a.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

PROCEEDINGS OF THE 39TH ANNUAL GENERAL MEETING OF THE COMPANY HELD ON FRIDAY, THE 30TH DAY OF SEPTEMBER, 2022 AT 10.30 A.M. AT THE REGISTERED OFFICE AT NATCO HOUSE, ROAD NO.2, BANJARA HILLS, HYDERABAD 500 034, TELANGANA, INDIA THROUGH VIDEO CONFERENCE

Directors personally present at the registered office

- | | |
|---------------------------|--|
| 1. Sri G.S. Murthy | Chairman and Independent Director,
Chairman of the Audit Committee,
Stakeholders Relationship Committee and
Corporate Social Responsibility Committee |
| 2. Sri V.C. Nannapaneni | Managing Director |
| 3. Sri Rajeev Nannapaneni | Director & CEO |

Directors present through video conference from their respective places

- | | |
|-----------------------------|---|
| 4. Dr. T.V. Rao | Independent Director and Chairman of the
Nomination and Remuneration Committee |
| 5. Sri D.G. Prasad | Independent Director |
| 6. Dr. Leela Digumarti | Independent Director |
| 7. Sri P.S.R.K. Prasad | Director & Executive Vice President (CES) |
| 8. Dr. D. Linga Rao | Director & President (Tech. Affairs) |
| 9. Dr. M.U.R. Naidu | Independent Director |
| 10. Dr. Pavan Ganapati Bhat | Additional Director |

Company Secretary

CS Ch. Venkat Ramesh, Company Secretary & Compliance Officer

Others Present

- (i) Sri S.V.V.N. Appa Rao, Chief Financial Officer.
- (ii) CA Vikash Somani, Partner and CA Ankit Jalan, Associate Director, M/s.B S R & Associates LLP, Statutory Auditors
- (iii) CS B Kiran Kumar, Proprietor, BK & Associates, Practicing Company Secretary, Secretarial Auditors and Scrutinizer for the evoting process



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

A total of 86 members were present during the Annual General Meeting (AGM) through Video Conference.

The Company Secretary of the Company welcomed all the Members and Directors of the Company who were present to the AGM through Video Conference.

Sri G.S. Murthy, Chairman of the Company, occupied the Chair, conducted the proceedings of the meeting and informed that the requisite quorum was present to commence the proceedings:

- Chairman requested Sri Rajeev Nannapaneni, Director & Chief Executive Officer, to read out the Chairman's Speech. Accordingly, the Director & Chief Executive Officer presented the Chairman's Speech to the Members.
- The Chairman informed that with the permission of the Members the notice convening the meeting, Board's Report and other reports were taken as read. The report of Statutory Auditors is unqualified and without any adverse observations or comments in their report and the same was taken as read.
- The Chairman informed the members that the Company has provided remote e-voting facility to the Members from 27th September, 2022 (9.00 a.m.) to 29th September, 2022 (5.00 p.m.) in order to exercise their right to vote for the items of business of 39th AGM. Members who have not availed the remote e-voting facility, for those members e-voting during the AGM has been provided.
- The following items of business were considered at the AGM:

ORDINARY BUSINESS:	
1	Adoption of audited Annual Financial Statements for the Financial Year 2021-22
2	To confirm three interim dividends aggregating to Rs.4.50 per share paid on equity shares during the Financial Year 2021-22 as dividend for the FY 2021-22.
3	Reappointment of Dr. D. Linga Rao (DIN: 07088404) as a Director liable to retire by rotation
SPECIAL BUSINESS:	
4	Ratification of remuneration of Cost Auditors.
5	Appointment of Dr. Pavan Ganapati Bhat (DIN: 09691260) as Director & Executive Vice President (Technical Operations) of the Company



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

- Chairman instructed the moderator for the VC to enable the Speaker shareholders to raise the comments/queries with regard to the reports and accounts. Director & CEO, and CFO appropriately answered the queries raised by the members.
- The Chairman then informed that the combined results on the remote e-voting and e-voting during the AGM would be announced within forty-eight hours of conclusion of the AGM.
- The Company Secretary of the meeting thanked the Members for their active participation in the AGM and declared that the business for which the AGM is convened is completed.

The meeting was concluded at 11.25 a.m.

Thanking you,

Yours Faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer